In The Spotlight
Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, and ERS Genomics have extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology.
ADC Biotechnology (ADC Bio) predicts that the next crucial phase of innovation to optimise and streamline production processes of ADCs will be designed at the clinical development stage by specialist, ADC focused service providers.
Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.
GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting the Anti-Müllerian Hormone Receptor II (AMHRII) for the treatment of cancer, announces that it has dosed the first patient in its Phase 2 clinical trial - of GM102 single agent and in combination with Trifluridine/Tipiracil (Lonsurf) - in patients with advanced or metastatic colorectal cancer (CRC).
Thrombolytic Science, LLC (TSI) today announced initiation of a Phase 2 clinical trial to confirm the efficacy and safety of its sequential dual-treatment regimen of low-dose tissue plasminogen activator (tPA) and HisproUK (TSI’s mutant prourokinase [proUK]) in patients who have experienced ischemic stroke.
CRF Health, the leading provider of patient-centered eSource technology solutions for the life sciences industry, announced that its TrialMax® Slate solution has been selected by a US biotech company for a global Phase III prostate cancer study.
Multisorb, the leading provider of oxygen and moisture management technologies, announced the inauguration of a new manufacturing facility in Hyderabad, India.
Medical Technology company IME Medical Electrospinning, developer, producer and scientific partner in the field of biomedical electrospinning processes and equipment, announced that its high-end laboratory and a brand new set of cleanrooms have become operational.
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Antengene Corporation, a biopharmaceutical company, recently announced a strategic partnership for the CMC development and manufacturing of innovative oncology drugs.
CEIV Pharma (the Center of Excellence for Independent Validators in Pharmaceutical Logistics) certification is a quality assurance program for the temperature-controlled transportation of pharmaceutical products, developed by the International Air Transport Association (IATA).
Smart Skin Technologies and SCHOTT have announced plans to enter into a strategic cooperation.
Recipharm, a leading contract development and manufacturing organisation (CDMO), has released its first serialised products to Europe from its facilities in Lisbon, Portugal and Stockholm, Sweden.